Novo Nordisk A/s

Novo Nordiskals

Birgitte Schjellerup Wulff

Soeren Oestergaard

Birgit Wieczorek

Kilian Waldemar Conde Frieboes

Jens Kaalby Thomsen

Carsten Jessen

Klaus Rudolf

Knud Erik Andersen

Dirk Stenkamp

Rudolf Hurnaus

Thomas Kruse Hansen

Ingrid Pettersson

Bernd Peschke

Nils Langeland Johansen

Kjeld Madsen

Lars Thim

Leif Hoejslet Christensen

Ulrich Sensfuss

Jens Juul Holst

Florencio Zaragoza Dörwald

Birgitte Nissen

Bernd Krist

Andreas Vegge

Martin Edward Judge

Ole Dragsbaek Madsen

Kilian Waldemar Conde-Frieboes

Tine Krogh Jørgensen

Stephan Georg Müller

Annika Sanfridson

Søren ØStergaard

Betty Lomstein Pedersen

Ole Madsen

Martin Judge

Jens Holst

The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

HPYY(1-36) having a beta-homoarginine substitution at position 35

The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Selective PYY compounds and uses thereof

The invention relates to PYY compounds with the amino acid modifications 7Lys, 30Trp, and 31Leu, and in addition to these, 22Ile and/or 28Tyr, and derivatives thereof. The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.

Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-Rcomprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases.

Melanocortin receptor agonists

Disclosed is a novel class of substituted imidazole compounds, pharmaceutical compositions containing them and uses of these compounds in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, these compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial. These imidazoles compounds have the formula Iwherein R, R, R, R, R, R, A, X, Y and Z are as defined in the specification.

Substituted imidazoles, their preparation and use

The present invention relates to appetite-suppressing peptides or an appetite-suppressing peptide-containing fraction for the treatment of obesity or type II diabetes.

Use of a pharmaceutical composition comprising an appetite-suppressing

Growing community of inventors

Virum, Denmark

Birgitte Schjellerup Wulff